Aminosalicylates have been suggested as chemopreventive agents for colorectal cancer in ulcerative colitis.
Dr David Rubin and colleagues from Illinois studied the effect of aminosalicylate use on dysplasia and colorectal cancer risk in chronic ulcerative colitis.
Ulcerative colitis patients with dysplasia or colorectal cancer were matched with controls by disease duration, extent, and age at diagnosis.
|27% of cases had a family history of colorectal cancer|
|Clinical Gastroenterology & Hepatology|
The research team calculated the total amount of aminosalicylates over the duration of the disease as well as the mean daily amount of drug.
The team used conditional logistic regression to examine the relationship of aminosalicylates to the risk of neoplasia.
Conditional logistic regression adjusted for disease duration, age at diagnosis, and family history of colorectal cancer.
The researchers controlled potential confounders in a multivariable model.
The research team matched 26 cases with 96 controls.
Cases and controls were similar in age, age at diagnosis of ulcerative colitis, duration of ulcerative colitis, extent of disease, and sex.
The researchers noted that the 2 groups were also similar in terms of family history of ulcerative colitis, primary sclerosing cholangitis, and smoking.
The team found that 27% of cases had a family history of colorectal cancer vs 9% of controls.
The team showed that aminosalicylate use of 1.2 g/day or more was associated with a 72% reduction in the odds of dysplasia or colorectal cancer.
As the total dose of aminosalicylates increased, the team observed that the odds of dysplasia or colorectal cancer decreased.
Dr Rubin's team concludes, “This case-control study shows a significant risk reduction of dysplasia and colorectal cancer in ulcerative colitis patients exposed to aminosalicylate therapy.”